Topoisomerases and Anthracyclines: Recent Advances and Perspectives in Anticancer Therapy and Prevention of Cardiotoxicity

Author(s): Alvaro Mordente*, Elisabetta Meucci, Giuseppe Ettore Martorana, Daniela Tavian, Andrea Silvestrini*

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 15 , 2017

  Journal Home
Translate in Chinese
Become EABM
Become Reviewer


Topoisomerases are ubiquitous enzymes involved in maintaining genomic stability of the cell by regulating the over- or underwinding of DNA strands. Besides their customary functions, topoisomerases are important cellular targets of widely used anticancer drugs. In particular, topoisomerase IIα (Top2α) has been postulated as the primary molecular target of anthracycline’s anticancer activity, whereas topoisomerase IIβ (Top2β), the only Top2 present in heart tissue, seems to be involved in the development of anthracycline-induced cardiotoxicity. Noteworthy, cardiotoxicity is the most frequent adverse effect of both conventional and modern anticancer targeted therapy, representing the leading noncancer-related cause of morbidity and mortality in long-term survivors. The molecular mechanisms of anthracyclineinduced cardiotoxicity have been investigated for decades and, despite the numerous mechanistic hypotheses put forward, its aetiology and pathogenesis still remain controversial.

This review is aimed at focusing on the double edge sword of topoisomerase-anthracycline interaction, and, in particular, on the potential role of topoisomerases in anthracyclines anticancer activity as well as in the pathogenesis of anthracycline-induced cardiotoxicity.

Keywords: Anthracycline, cancer chemotherapy, cardio-oncology, cardiotoxicity, catalytic inhibitors, DNA topoisomerases, topoisomerase poisons.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [1607 - 1626]
Pages: 20
DOI: 10.2174/0929867323666161214120355
Price: $65

Article Metrics

PDF: 61